Associated equity: Oryzon Genomics
Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for haematology-oncology, where the strategic priority is in first-line acute myeloid leukaemia; there is potential for an accelerated approval pathway should clinical data continue to be supportive. It is also being evaluated in other indications, such as myelodysplastic syndrome, myeloproliferative neoplasms and sickle cell disease, as well as in small cell lung cancer. Central nervous system asset vafidemstat has completed a Phase IIb trial in borderline personality disorder and preparations are underway for Phase III. It is also currently involved in a Phase IIb trial for schizophrenia, and management is preparing for an additional Phase II trial in autism spectrum disorder.
Oryzon Genomics — 3 videos in collection
Oryzon Genomics is a Spanish biotechnology company focused on epigenetics. Its two lead assets, vafidemstat (central nervous system, CNS) and iadademstat (oncology), are in the clinical stages of development for various indications. Both are small molecule inhibitors of LSD1, a histone-modifying enzyme that forms part of complexes responsible for the regulation of genes implicated in CNS disorders and cancer.
Listen on your preferred podcast player below:
About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.